S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Options Trading Plan–Perfect For Beginners (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Options Trading Plan–Perfect For Beginners (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
At UN, African leaders say enough is enough: They must be partnered with, not sidelined
Options Trading Plan–Perfect For Beginners (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Leading Egyptian opposition politician targeted with spyware, researchers find
NASDAQ:VIR

Vir Biotechnology (VIR) Stock Forecast, Price & News

$9.35
+0.21 (+2.30%)
(As of 09/22/2023 ET)
Compare
Today's Range
$8.90
$9.52
50-Day Range
$9.14
$23.05
52-Week Range
$8.90
$31.55
Volume
2.26 million shs
Average Volume
1.76 million shs
Market Capitalization
$1.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.11

Vir Biotechnology MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
296.9% Upside
$37.11 Price Target
Short Interest
Healthy
5.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.49mentions of Vir Biotechnology in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$637,408 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($4.66) to ($4.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.63 out of 5 stars

Medical Sector

117th out of 965 stocks

Biological Products, Except Diagnostic Industry

11th out of 160 stocks


VIR stock logo

About Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

VIR Price History

VIR Stock News Headlines

This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
New gold-backed currency could kill the Dollar
Rumors are circulating of a new currency that will be backed by gold. A huge story, if true. And while it’s impossible to know how it will pan out, there’s one important move you should make right now, before this happens. It’s the best way to protect your wealth today. Because if you’re not careful, YOU could be the one who pays the price
Akero Therapeutics (AKRO) Gets a Buy from J.P. Morgan
Vir Biotechnology (VIR) Receives a Buy from H.C. Wainwright
Barclays Keeps Their Buy Rating on Vir Biotechnology (VIR)
See More Headlines
Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

VIR Company Calendar

Last Earnings
8/03/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIR
Fax
N/A
Employees
576
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.11
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+296.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$515.84 million
Pretax Margin
-55.98%

Debt

Sales & Book Value

Annual Sales
$1.62 billion
Cash Flow
$3.95 per share
Book Value
$15.61 per share

Miscellaneous

Free Float
109,952,000
Market Cap
$1.26 billion
Optionable
Optionable
Beta
0.16
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Ms. Johanna Friedl-Naderer (Age 55)
    Exec. VP & COO
    Comp: $1.92M
  • Dr. Ann M. Hanly Ph.D. (Age 53)
    Exec. VP & Chief Technology Officer
    Comp: $842.23k
  • Dr. Phillip Pang M.D. (Age 48)
    Ph.D., Exec. VP, Chief Medical Officer & Interim Head of Research
    Comp: $837.38k
  • Dr. Marianne De Backer M.B.A. (Age 54)
    M.Sc., Ph.D., CEO & Director
  • Dr. Klaus Frueh Ph.D. (Age 63)
    Co-Founder & Scientific Advisor
  • Dr. Lawrence Corey M.D. (Age 76)
    Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker M.D.
    Co-Founder & Scientific Advisor
  • Mr. Sung H. Lee (Age 53)
    Exec. VP & CFO
  • Ms. Heather Rowe Armstrong
    VP of Investor Relations
  • Ms. Vanina De Verneuil J.D.
    Sr. VP of Legal & Corp. Sec.













VIR Stock - Frequently Asked Questions

Should I buy or sell Vir Biotechnology stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VIR shares.
View VIR analyst ratings
or view top-rated stocks.

What is Vir Biotechnology's stock price forecast for 2023?

8 brokerages have issued 12 month price objectives for Vir Biotechnology's shares. Their VIR share price forecasts range from $14.00 to $95.00. On average, they expect the company's share price to reach $37.11 in the next year. This suggests a possible upside of 296.9% from the stock's current price.
View analysts price targets for VIR
or view top-rated stocks among Wall Street analysts.

How have VIR shares performed in 2023?

Vir Biotechnology's stock was trading at $25.31 at the start of the year. Since then, VIR stock has decreased by 63.1% and is now trading at $9.35.
View the best growth stocks for 2023 here
.

When is Vir Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our VIR earnings forecast
.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) announced its earnings results on Thursday, August, 3rd. The company reported ($1.45) EPS for the quarter, missing analysts' consensus estimates of ($1.21) by $0.24. The company had revenue of $3.80 million for the quarter, compared to analyst estimates of $22.39 million. Vir Biotechnology had a negative trailing twelve-month return on equity of 13.08% and a negative net margin of 53.38%. The business's revenue was up 379999900.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.58) EPS.

What is George Scangos' approval rating as Vir Biotechnology's CEO?

7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.

When did Vir Biotechnology IPO?

(VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

What is Vir Biotechnology's stock symbol?

Vir Biotechnology trades on the NASDAQ under the ticker symbol "VIR."

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Bank Julius Baer & Co. Ltd Zurich (23.88%), SB Investment Advisers UK Ltd. (12.43%), BlackRock Inc. (10.41%), State Street Corp (4.04%), Temasek Holdings Private Ltd (3.82%) and Baillie Gifford & Co. (2.97%). Insiders that own company stock include Ann M Hanly, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Jay Parrish, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vir Biotechnology's stock price today?

One share of VIR stock can currently be purchased for approximately $9.35.

How much money does Vir Biotechnology make?

Vir Biotechnology (NASDAQ:VIR) has a market capitalization of $1.26 billion and generates $1.62 billion in revenue each year. The company earns $515.84 million in net income (profit) each year or ($1.97) on an earnings per share basis.

How many employees does Vir Biotechnology have?

The company employs 576 workers across the globe.

How can I contact Vir Biotechnology?

Vir Biotechnology's mailing address is 499 ILLINOIS STREET SUITE 500, SAN FRANCISCO CA, 94158. The official website for the company is www.vir.bio. The company can be reached via phone at 415-906-4324 or via email at ir@vir.bio.

This page (NASDAQ:VIR) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -